Zobrazeno 1 - 10
of 157
pro vyhledávání: '"Jeffrey H. Schwartz"'
Autor:
Jeffrey H. Schwartz, Erlyn Smith
Publikováno v:
Cancer Reports, Vol 5, Iss 10, Pp n/a-n/a (2022)
Abstract Background Prenatally identified suprarenal masses are most often found to be adrenal hemorrhage. The most common tumor in this situation is neuroblastoma. Case Presentation We report the case of a rare adrenocortical tumor found prenatally
Externí odkaz:
https://doaj.org/article/ba624e44e80e4b4e8c78256cda57ef74
Publikováno v:
Orphanet Journal of Rare Diseases, Vol 13, Iss 1, Pp 1-7 (2018)
Abstract Background Emerging evidence suggests that several factors can impact disease progression in transthyretin amyloid polyneuropathy (ATTR-PN). The present analysis used longitudinal data from Val30Met patients participating in the tafamidis (s
Externí odkaz:
https://doaj.org/article/f6789ecb5f5142fc92d1e2cff64488e1
Autor:
Jeffrey H. Schwartz
Publikováno v:
Revista Mexicana de Biodiversidad, Vol 82, Iss 1, Pp 1-18 (2011)
The history of systematics and evolutionary biology demonstrates how greatly the "modern evolutionary synthesis" instrumentally prevented, rather than facilitated, the intellectual growth and maturity of the diversity of evolutionary disciplines. In
Externí odkaz:
https://doaj.org/article/ef3218700d81406690b0dc744eebf12a
Publikováno v:
The Anatomical Record. 305:1991-2029
Circum-nasal and nasal cavity morphology add to the picture of the Sima de los Huesos specimens as, at one level, representing a distinct morph and, at another, displaying individual variation. They developed a robust, midline-grooved, three-dimensio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fbd95ae292e4e408f7c0d0c407d2c217
https://doi.org/10.1002/ar.24698
https://doi.org/10.1002/ar.24698
Autor:
Michelle Stewart, Jeffrey H. Schwartz, Balarama Gundapaneni, Mathew S. Maurer, Martha Grogan, Mazen Hanna, Terrell A. Patterson, Marla B. Sultan, Thibaud Damy
Publikováno v:
The American Journal of Cardiology. 141:98-105
In the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial, tafamidis significantly reduced all-cause mortality and cardiovascular-related hospitalizations in patients with transthyretin amyloid cardiomyopathy (ATTR-CM). ATTR-CM is associated wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6aaff86afd94638b51e3107cdc5e6de1
https://doi.org/10.1016/j.amjcard.2020.10.066
https://doi.org/10.1016/j.amjcard.2020.10.066
Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy
Autor:
Terrell A. Patterson, Balarama Gundapaneni, Eric J. Velazquez, Perry M. Elliott, Mathew S. Maurer, Thibaud Damy, Marla B. Sultan, Claudio Rapezzi, Kurt Boman, John L. Berk, Jose Nativi-Nicolau, Jeffrey H. Schwartz
Publikováno v:
JACC: Heart Failure. 9:115-123
Objectives Tafamidis is an effective treatment for transthyretin amyloid cardiomyopathy (ATTR-CM), this study aimed to determine whether there is a differential effect between variant transthyretin amyloidosis (ATTRv) and wild-type transthyretin (ATT
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2c9bb861134ebee9bbf4149323470f9d
https://doi.org/10.1016/j.jchf.2020.09.011
https://doi.org/10.1016/j.jchf.2020.09.011
Autor:
Huihua Li, Ben Ebede, Jeffrey H. Schwartz, Marla B. Sultan, Peter Huber, Alison Flynn, Balarama Gundapaneni, Denise Rill
Publikováno v:
Amyloid. 26:203-209
Background: Tafamidis is approved in over 40 countries to delay neurologic progression in patients with transthyretin amyloid polyneuropathy (ATTR-PN). A comprehensive, integrated analysis of safety data from interventional, observational and surveil
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d563d65e4ea252ddbea136d94dae6a59
https://doi.org/10.1080/13506129.2019.1643714
https://doi.org/10.1080/13506129.2019.1643714
Autor:
Jeffrey H. Schwartz
Publikováno v:
Evolutionary Biology – New Perspectives on Its Development ISBN: 9783030655358
As Darwin originally conceived it, natural selection not only chose features that, in retrospect, would allow those with them to be better adapted to their immediate circumstances—it was also the agent provocateur of the pool of variation from whic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::09d3c35cf95d4dff95a9440d391ad837
https://doi.org/10.1007/978-3-030-65536-5_12
https://doi.org/10.1007/978-3-030-65536-5_12
Autor:
Omar Niss, Robert B. Lorsbach, Mikaela Berger, Satheesh Chonat, Morgan McLemore, David Buchbinder, Timothy McCavit, Linda G. Shaffer, Jessica Simpson, Jeffrey H. Schwartz, Jessica Meznarich, Myesa Emberesh, Katie G. Seu, Wenying Zhang, Theodosia A. Kalfa, Ammar Husami, Theodosia Kalfa, Robert Lorsbach, Carolyn Lutzko, Adam Nelson, Charles Quinn, Clarissa Johnson, Jennifer A. Rothman, Sweta Gupta, Mara Nuñez Toscano, Melissa Forouhar, Vinod K. Gidvani-Diaz, James B. Ball, Gavin D. Roach, KayeLyn Wagner, Sam Milanovich, James Boyer, Jane Chawla, Christine Moore Smith, Adrienne Lee, Vlad C. Radulescu, Yasmina L. Abajas, A. Kim Ritchey, Hunter R. Underhill, Yaddanapudi Ravindranath, Niketa C. Shah
Publikováno v:
Blood Cells Mol Dis
Congenital dyserythropoietic anemias (CDAs) are characterized by ineffective erythropoiesis and distinctive erythroblast abnormalities; the diagnosis is often missed or delayed due to significant phenotypic heterogeneity. We established the CDA Regis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6456eca53dbaf10f48ac098fb79414e7
https://pubmed.ncbi.nlm.nih.gov/33401150
https://pubmed.ncbi.nlm.nih.gov/33401150
Autor:
Steven Riley, Giampaolo Merlini, Marla B. Sultan, Jeffrey H. Schwartz, Pablo García-Pavía, Terrell A. Patterson, Mazen Hanna, Ronald M. Witteles, Balarama Gundapaneni, Thibaud Damy, Daniel P. Judge
Publikováno v:
DDFV. Repositorio Institucional de la Universidad Francisco de Vitoria
instname
DDFV: Repositorio Institucional de la Universidad Francisco de Vitoria
Universidad Francisco de Vitoria
instname
DDFV: Repositorio Institucional de la Universidad Francisco de Vitoria
Universidad Francisco de Vitoria
Aims Tafamidis is an effective treatment for transthyretin amyloid cardiomyopathy (ATTR-CM) in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT). While ATTR-ACT was not designed for a dose-specific assessment, further analysis f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49968f6aace6ced155cd44039a776323
http://hdl.handle.net/10641/2158
http://hdl.handle.net/10641/2158